This biotechnology company develops proprietary cells-on-a-chip eye models that simulate ocular environmental conditions, including tear flow and the liquid-air interface of the corneal surface. These models serve as pre-clinical screening platforms for ocular therapeutic discovery and delivery, enabling more effective research into eye diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for preclinical ocular drug development often fail to accurately replicate the complex environment of the human eye, leading to ineffective therapeutic candidates and high failure rates in clinical trials. Traditional in vitro models lack the dynamic conditions of the ocular surface, such as tear flow and the air-liquid interface, while in vivo models are expensive, time-consuming, and raise ethical concerns.
Solution
EyesoBio offers a proprietary cell-on-a-chip platform that mimics the physiological conditions of the human eye, providing a more predictive and efficient preclinical screening tool for ocular therapeutics. The microfluidic device replicates the tear flow and air-liquid interface of the corneal surface, enabling researchers to study the effects of drug candidates, formulations, and biomaterials on human ocular cells in a dynamic environment. Compatible with standard laboratory microscopes, the platform supports continuous, time-lapse imaging, providing real-time phenotypic data. EyesoBio's platform aims to accelerate the identification of promising therapeutic candidates and reduce the risk of clinical trial failures.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and academic researchers involved in ocular drug discovery and development.
Features
- Proprietary cell-on-a-chip design that replicates the tear flow and air-liquid interface of the corneal surface
- Microfluidic system for dynamic modeling of the ocular environment
- Compatibility with standard laboratory microscopes for time-lapse imaging
- Computational imaging software (in development) for real-time phenotypic analysis
- Enables testing of therapeutics, formulations, and eluted drugs from biomaterials on human ocular cells